Novo, Roche, GlaxoSmithKline and Novartis, all of which participated in a $41m round for Alios in April, exited the pharmaceutical company, which was bought by Johnson & Johnson.
Pharmaceutical company Johnson & Johnson agreed yesterday to buy Alios BioPharma, a US-based developer of drugs to treat viral diseases, for $1.75bn in cash.
Exiting investors include Novo Ventures, SR One, Roche Venture Fund and Novartis Ventures, which respectively act as the respective corporate venturing arms of pharmaceutical firms Novo, GlaxoSmithKline, Roche and Novartis.
Alios had raised $32m in a 2009 series A round, which was followed by a $41m series B in April this year.
As part of the…
